Canopus BioPharma study confirms efficacy of CB008 drug for Ebola Virus inhibition

Canopus BioPharma Inc. (OTC Pink: CBIA) today announces that it has completed crucial research in confirming efficacy of a prescription drug: CB008 for Ebola Virus inhibition.

Laboratories at the Texas Biomedical Research Institute in San Antonio Texas have demonstrated complete in-vitro inhibition of the live Ebola Virus strain Zaire at concentrations of CB008 that are achievable by oral administration. CB008 is only one of a family of prescription drugs which has been demonstrated by Canopus BioPharma to have potential in preventing Hemorrhagic syndrome and inhibiting Ebola Viral replication.

CB008 is an in-house codename for a well-established prescription drug first approved by the FDA in the early 1980's for other medical indications. CB008 is an effective, safe treatment for Ebola Virus. Canopus BioPharma has signed a confidential agreement with a major pharmaceutical company who are reviewing the results and the possibility of expediting an Ebola non-human primate study. Following this, CB008 can progress to a human Ebola patient clinical trial in West Africa.

According to the CDC, the 2014 Ebola Virus epidemic is the largest in history and is effecting multiple countries. In this epidemic, 1 in 2 people who get the disease die from it. It can take up to 21 days for an infected person to develop symptoms from it. The highly contagious virus is spread through contact with an infected persons blood or body fluids."What we have shown by the use of CB008 in tissue culture is how vulnerable these Ebola viruses are when you interfere with their mechanism of creating havoc both to epithelial cells and to the immune system," said Dr. Leo Shanahan-Prendergast from Canopus BioPharma Inc.